Ophthalmology Overview: How Chronic Pain Impacts the Cornea, Dry Eye Disease in Postmenopausal Women, and More
Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.
Highlighting the latest
Evaluating the Link Between Chronic Pain and Corneal Sensitivity
Although eye conditions are typically responsible for altering corneal sensitivity, research presented at the ARVO 2021 virtual annual meeting indicated that chronic pain syndromes involving the trigeminal system, as well as depression and worse quality of life, may also cause greater corneal sensitivity in patients.
Reported by
Based on findings, patients of the trigeminal pain group exhibited significantly lower mean corneal mechanical detection threshold (ie, higher sensitivity) than the non-trigeminal pain group. In addition to pain phenotypes, factors that may also influence corneal sensitivity included higher depression score, Black race, dyslipidemia, and continuous positive airway pressure (CPAP) use.
Eye Drop Formulation Found to Reduce DED Burden in Postmenopausal Women
As reported by
With sex hormone involvement suggested to play a central role in the pathogenesis of DED, postmenopausal women have been associated with an elevated incidence. The formulation, called RP101, contained 17-beta-estradiol as the active ingredient and a sterile isotonic thermogelling solution as the drug delivery system, and was randomly administered in 3 different dosages to postmenopausal female patients involved in the controlled, parallel-group study. The control group was given solely the isotonic thermogelling solution.
In evaluating the safety and optimal dosing of RP101, patients given the highest dosage of the formulation were significantly associated with the greatest reductions in staining of the inferior cornea, compared with the control group (P = .0463). The formulation was indicated to be well tolerated, with patients of all 4 treatment arms showing a decrease in symptoms of DED.
Positive Topline Results Reported in Phase 3 Trial of Investigational Therapy for IOP
Findings of a phase 3 trial this week found that netarsudil ophthalmic solution 0.02% (Rhopressa) met its primary endpoint in achieving significantly reduced intraocular pressure (IOP) in patients after 4 weeks compared with treatment of ripasudil hydrochloride hydrate ophthalmic solution 0.4% (Rhokiinsa).
Reported by
At 4 weeks, netarsudil 0.02% was found to reduce mean diurnal IOP by 4.7 mmHg (22.6%) from baseline compared with 3.0 mmHg (14.3%) with ripasudil 0.4% (P < .0001). Both therapies were shown to be well-tolerated, with conjunctival hyperemia serving as the most common treatment-related adverse event.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Climate Change Impacts Allergy Health Risks: Gary Falcetano, PA-C, AE-C
September 18th 2025
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025